Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Next Previous
Search
Trial Profile

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INO 8000 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors GeneOne Life Science

    • Most Recent Events

    • 22 May 2020 Status changed from recruiting to completed.
    • 14 Sep 2018 New trial record
    • 04 Sep 2018 According to an Inovio Pharmaceuticals media release, first patient has been doses in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top